KENDALL & TAYLOR ATKINSON FOUNDATION

**ALLOCATIONS WERE MADE TO THE FANCONI ANEMIA RESEARCH FUND TO SUPPORT MEDICAL, SCIENTIFIC AND TREATMENT RESEARCH OF FANCONI ANEMIA AND ITS RELATED CANCERS.*$72,513 WAS ALLOCATED TO FUND RESEARCH ENTITLED "TRANSFORMING TREATMENT OF INHERITED BONE MARROW FAILURE IN FANCONI ANEMIA BY PRECISE IN VIVO GENOME EDITING."PEOPLE WITH FA, WHO HAVE BONE MARROW FAILURE, ARE CURRENTLY TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS. HOWEVER, THESE PROCEDURES REMAIN SOMEWHAT LIMITED DUE TO HIGH COST, LACK OF APPROPRIATE DONORS IN SOME REGIONS, AND HEIGHTENED RISK OF LONG-TERM HEALTH EFFECTS SUCH AS AN INCREASED RISK OF CANCER. IN VIVO GENE THERAPIES OFFER PROMISE AND GREAT POTENTIAL FOR A SAGE EASILY ACCESSIBLE, AND COST-EFFECTIVE THERAPEUTIC OPTION TO TREAT FA-RELATED BONE MARROW FAILURE THAT CAN BE USED WORLDWIDE. THIS CONSORTIUM WILL TEST GENE EDITING TECHNOLOGIES FOR ALL MAJOR FA MUTATIONS USING LABORATORY-BASED TECHNIQUES OVER THE NEXT TWO YEARS. THE GOAL IS TO RAPIDLY DEVELOP A TRANSLATIONAL PROTOCOL THAT WILL EVENTUALLY BE TESTED IN CLINICAL TRIALS.**ALLOCATIONS WERE MADE TO THE UNIVERSITY OF COLORADO FOUNDATION. *AN ALLOCATION OF $20,000 WAS MADE TO THE UNIVERSITY OF COLORADO FOUNDATION FOR THE KENNETH R ATKINSON MD ENDOWED MEMORIAL SCHOLARSHIP.DISTRIBUTION OF FUNDS WAS MADE TO AN ENDOWED SCHOLARSHIP TO BE AWARDED ANNUALLY TO A STUDENT ENROLLED IN THE SCHOOL OF MEDICINE AT THE UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS. SCHOLARSHIP IS NEED BASED WITH PREFERENCE GIVEN TO 4TH YEAR MEDICAL STUDENTS WHO PLAN ON GOING INTO PRIMARY CARE MEDICINE. PREFERENCE WILL ALSO BE GIVEN TO STUDENTS INTENDING TO PRACTICE PRIMARY CARE IN THE STATE OF COLORADO.